From: Favorable response to doxorubicin combination chemotherapy does not yield good clinical outcome in patients with metastatic breast cancer with triple-negative phenotype
P value
Hazard Ratio (HR)
95% CI
Triple negativity
0.011
2.03
1.17
3.51
HER2 positivity
0.027
1.86
1.07
3.22